medigraphic.com
ISSN 1561-3194 (Electronic)

2022, Number 2

<< Back Next >>

Rev Ciencias Médicas 2022; 26 (2)

Clinical-epidemiologic characteristics and therapeutic management of kidney cancer

Suárez-Alfonso OE, Castillo-García I, Hernández-Campo PR, Díaz-Dueñas Y, Zayas-Veliz R

Language: Spanish
References: 20
Page: 1-12
PDF size: 445.97 Kb.


ABSTRACT

Introduction: kidney cancer represents 2 % of genitourinary neoplasms; it is usually diagnosed between the fourth and sixth decade of life.
Objective: to characterize the clinical-epidemiological behavior and therapeutic management of renal cell carcinoma in Pinar del Rio during 2016-2019.
Methods: a descriptive, retrospective study was conducted in Pinar del Rio from 2016 to 2019, with a target group of 26 patients treated by renal cancer surgery and a sample comprising 21 patients who attended the Oncology Care Center (III Congreso). Clinical history information was collected: age, gender and skin color, symptoms at diagnosis, affected kidney, clinical stages, histology and treatment. A database was prepared where qualitative variables were expressed in absolute frequencies and relative frequencies in percentages.
Results: there was a predominance in the age bracket 70 years and over with 8 patients (33,3 %), most of them asymptomatic 12 (60 %), with a greater involvement of the left kidney 15 (71,4 %) and 7 (33,3 %) in the middle part. Histologically corresponding to the clear cell type 16 (76,2 %), diagnosed 15 (71,4 %) in stage I, with total nephrectomy 20 (95,2 %).
Conclusions: renal cancer predominated in the eighth decade of life, male, asymptomatic at diagnosis, with more involvement of the left kidney in the middle part. Histologically corresponding to clear cells with nuclear grade II, without vascular or lymphatic invasion or thrombi in the renal vein, diagnosed in stage I, mostly treated with total nephrectomy.


REFERENCES

  1. Global Burden of Disease Cancer Collaboration, Fitzmaurice C, Akinyemiju TF, Al Lami FH, Alam T, Alizadeh-Navaei R, et al. A Systematic Analysis for the Global Burden of Disease Study. JAMA Oncol. [Internet] 2018 Nov 1 [citado: 14/01/2020]; 4(11):1553-1568. Disponible en: Disponible en: https://pubmed.ncbi.nlm.nih.gov/29860482/ 1.

  2. Bazalytska SV, Persidsky Y, Romanenko AM. Моlecular mechanisms of initiation of carcinogenesis in the testis. ExpOncol [Internet]. 2019 [citado: 14/01/2020]; 41(3):224-34. Disponible en: Disponible en: https://pubmed.ncbi.nlm.nih.gov/31569932/ 2.

  3. Craven RA, Vasudev NS, Banks RE. Proteomics and the search for biomarkers for renal cáncer. ClinBiochem [Internet]. 2013 [citado: 14/01/2020]; 46(6): 456-65. Disponible en: Disponible en: https://pubmed.ncbi.nlm.nih.gov/23228867/ 3.

  4. Anido Herranz U, González Del alba MA. Cáncer renal [Internet]. SEOM; 2019 [citado: 01/03/2020]. Disponible en: Disponible en: https://seom.org/info-sobre-el-cancer/renal 4.

  5. García García A, Guerra Román FB, García Morales I. Enucleación simple en el tratamiento de los tumores renales. Rev. Cubana Urol [Internet]. 2017 [citado 20/08/2021]; 6(1): 13-24. Disponible en: Disponible en: http://www.revurologia.sld.cu/index.php/rcu/article/view/285 5.

  6. Sekar RR, Patil D, Baum Y, Pearl J, Bausum A, Bilen MA, et al. A novel preoperative inflammatory marker prognostic score in patients with localized and metastatic renal cell carcinoma. Asian Journal of Urology [Internet]. 2017 [citado: 03/06/2020]; 4(4): 230-238. Disponible en: Disponible en: http://dx.doi.org/10.1016/j.ajur.2017.04.002 6.

  7. Turajlic S, Swanton C, Boshoff C. Kidney cancer: the next decade. J ExpMed [Internet]. 2018 [citado: 16 /09/2020]; 215(10): 2477-9. Disponible en: Disponible en: https://pubmed.ncbi.nlm.nih.gov/30217855/ 7.

  8. Gulley JL, Rajan A, Spigel DR. Avelumab for patients with previously treated metastatic or recurrent non-smallcell lung cancer (JAVELIN Solid Tumor): dose-expansion cohort of a multicentre, open-label, phase 1b trial. LancetOncol [Internet]. 2017 [citado: 23/12/2020]; 18(5): 599-610. Disponible en: Disponible en: https://pubmed.ncbi.nlm.nih.gov/28373005/ 8.

  9. National Comprehensive Cancer Network. NCCN guidelines: Kidney Cancer. [Internet] 2017. [citado: 10/09/2020]. Disponible en: Disponible en: https://www.nccn.org/patients/guidelines/content/PDF/kidney-spanish-patient.pdf 9.

  10. Cuba, Ministerio de Salud Pública. Anuario estadístico [Internet] La Habana: MINSAP; 2018 [citado: 23/12/2020]. Disponible en: Disponible en: https://salud.msp.gob.cu/tag/anuario-estadistico-de-salud/ 10.

  11. González León T, Morera Pérez M. Renal Cancer in theElderly. CurrUrolRep [Internet] 2016 [citado: 10/09/2020]; 17(1): 6. Disponible en: Disponible en: https://pubmed.ncbi.nlm.nih.gov/26715222/ 11.

  12. Sirohi D, Smith SC, Agarwal N, Maughan BL. Unclassified renal cell carcinoma: diagnostic difficulties and treatment modalities. Res RepUrol [Internet]. 2018 [citado: 10/09/2020]; 10: 205-17. Disponible en: Disponible en: https://pubmed.ncbi.nlm.nih.gov/30510921/ 12.

  13. Shingarev R, Jaimes EA. Renal cell carcinoma: new insights and challenges for a clinician scientist. Am J Physiol Renal Physiol [Internet]. 2017 [citado: 10/09/2020]; 313(2): 145-54. Disponible en: Disponible en: https://pubmed.ncbi.nlm.nih.gov/28381462/ 13.

  14. Wang ZJ, Westphalen AC, Zagoria RJ. CT and MRI of small renal masses. Br J Radiol [Internet]. 2018 [citado: 10/09/2020]; 91(1087): 20180131. Disponible en: Disponible en: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6221773/ 14.

  15. Wang Y, Ding Y, Wang J, Gu M, Wang Z, Qin C. Clinical features and survival analysis of clear cell papillary renal cell carcinoma: A 10‑year retrospective study from two institutions. OncologyLetters [Internet]. 2018 [citado: 10/09/2020]; 16(1): 1010-22. Disponible en: Disponible en: https://pubmed.ncbi.nlm.nih.gov/29963177/ 15.

  16. Acosta Jiménez E, Jerónimo Guerrero D, Macías Clavijo MA, Rivera Diez D, Hernández Briseño L, Beltrán Suárez E, et al. Carcinoma de células renales: factores patológicos pronósticos, estadificación y clasificación histopatológica. Rev Med Inst Mex Seguro Soc [Internet]. 2015 [citado: 14/01/2021]; 53(4): 454-65. Disponible en: Disponible en: https://www.medigraphic.com/cgi-bin/new/resumen.cgi?IDARTICULO=62587 16.

  17. Nguyen KA, Syed JS, Shuch B. Hereditary Kidney Cancer Syndromes and Surgical Management of the Small Renal Mass. Urol Clin North Am [Internet]. 2017 [citado: 14/01/2021]; 44 (2): 155-67. Disponible en: Disponible en: https://pubmed.ncbi.nlm.nih.gov/28411908/ 17.

  18. Rossi SH, Klatte T, Usher‑Smith J, Stewart GD. Epidemiology and screening for renal cáncer. World Journal of Urology [Internet]. 2018 [citado: 14/01/2021]; 36(9): 1341-53. Disponible en: Disponible en: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6105141/ 18.

  19. Bamias A, Escudier B, Sternberg CN, Zagouri F, Dellis A, Djavan B, et al. Current Clinical Practice Guidelines for the Treatment of Renal Cell Carcinoma: A Systematic Review and Critical Evaluation. Oncologist [Internet]. 2017 [citado: 14/01/2021]; 22(6): 667-79. Disponible en: Disponible en: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5469586/ 19.

  20. Klapperich ME, Jason Abel E, Ziemlewicz TJ, Best S, Lubner MG, Nakada SY, et al. Percutaneous Microwave Ablation of Stage T1a Renal Cell Carcinoma: A Single-Center, Retrospective Study. Radiology [Internet]. 2017 [citado: 14/01/2021]; 284(1): 272-80. Disponible en: Disponible en: https://pubmed.ncbi.nlm.nih.gov/28076721/ 20.




2020     |     www.medigraphic.com